Clinical Trials | December 29, 2025
Quantum BioPharma completes key toxicity studies for Lucid-MS, paving way for Phase 2 MS trial
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
The primary goal of the collaboration is joint research into trending and next-generation molecules
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
TactiFlex, the world’s first catheter with a flexible tip and contact?force sensing, allows doctors to deliver energy precisely and safely.
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
The update promises to revolutionize laboratory workflows by optimizing resources
The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital
Subscribe To Our Newsletter & Stay Updated
